ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Nano-drug codelivery system of vincristine and gemcitabine loaded hyaluronan-altered hollow mesoporous silica nanoparticles: investigation of in vitro drug release and anticancer activity in pancreatic cancer cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine-Resistant Pancreatic Tumors.Advanced nanobiomed research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study involves the co-loading of Vincristine (VC) and Gemcitabine (GT), two anticancer compounds, into hollow mesoporous silica nanoparticles (HA-SS-HMS) to specifically target pancreatic cancer cells, utilizing targeting and capping agent of hyaluronic acid (HA) and redox-sensitive linkers of S-S bonds. Well-dispersed HA-SS-HMS are fabricated with a diameter of less than 150 nm. Comprehensive chemical-physical characterization of the fabricated HA-SS-HMS utilized FTIR, FE-SEM, TEM, DLS, TGA, and BET techniques. The drug release experiment demonstrated regulated and pH-responsive behavior in the presence of HAase and GSH at pH levels 5.0 and 7.4. The targeting capability and dispersion of VC/GT@HA-SS-HMS in CD44(+) PANC- 1 pancreatic cancer cells were evidenced by fluorescence microscopic imaging. Furthermore, VC/GT@HA-SS-HMS demonstrated superior synergistic cytotoxicity and apoptotic rates relative to VC or GT-loaded HA-SS-HMS and the free VC/GT combination against the PANC- 1 cell line. The biochemical staining outcomes indicated a significant change in apoptosis ratio in cells treated with VC/GT@HA-SS-HMS. Collectively, our research demonstrates the promise of HA-SS-HMS as an effective nanoparticle-based approach for targeted and induced codelivery of VC/GT combination in the treatment of pancreatic cancer cells.
Indexed as
Identifiers
40266301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.